VCYT VERACYTE, INC.
FY2025 10-K
VERACYTE, INC. (VCYT) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: development and commercialization of genomic and molecular diagnostic tests for oncology and other indications
- • Emphasis on regulatory adaptations for IVDR/UKNI in Northern Ireland, and new Swiss IvDO aligning with IVDR from 2022
Management Discussion & Analysis
- • Revenue not explicitly stated; net income $66.4M in 2025 vs $24.1M in 2024, showing significant profitability improvement
- • Operating margin details not provided; net income growth from $24.1M (2024) to $66.4M (2025) indicates margin improvement
Risk Factors
- • Regulatory risk from Protecting Access to Medicare Act of 2014 (PAMA) may reduce test reimbursement rates, negatively impacting revenues and margins
- • Geopolitical risk from Middle East conflicts potentially disrupting Israel business and employees acquired in C2i Acquisition
Financial SummaryXBRL
Revenue
$517M
Net Income
$66M
Gross Margin
70.1%
Operating Margin
11.2%
Net Margin
12.8%
ROE
5.1%
Total Assets
$1.4B
EPS (Diluted)
$0.82
Operating Cash Flow
$136M
Source: XBRL data from VERACYTE, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on VERACYTE, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.